Wells Fargo’s Harvard Bioscience HBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-80
| Closed | -$356 | – | 7213 |
|
|
2025
Q2 | $356 | Sell |
80
-2,237
| -97% | -$9.35K | ﹤0.01% | 6407 |
|
|
2025
Q1 | $13.1K | Buy |
2,317
+51
| +2% | +$653 | ﹤0.01% | 5828 |
|
|
2024
Q4 | $47.8K | Buy |
2,266
+436
| +24% | +$10K | ﹤0.01% | 5501 |
|
|
2024
Q3 | $49.2K | Buy |
1,830
+47
| +3% | +$1.39K | ﹤0.01% | 5347 |
|
|
2024
Q2 | $50.8K | Buy |
1,783
+453
| +34% | +$15.9K | ﹤0.01% | 5284 |
|
|
2024
Q1 | $56.4K | Buy |
1,330
+162
| +14% | +$7.28K | ﹤0.01% | 5209 |
|
|
2023
Q4 | $62.5K | Buy |
1,168
+249
| +27% | +$11.2K | ﹤0.01% | 5186 |
|
|
2023
Q3 | $39.5K | Sell |
919
-728
| -44% | -$33.6K | ﹤0.01% | 5305 |
|
|
2023
Q2 | $90.4K | Buy |
1,647
+1,622
| +6,488% | +$89K | ﹤0.01% | 5108 |
|
|
2023
Q1 | $1.06K | Sell |
25
-500
| -95% | -$14.8K | ﹤0.01% | 6361 |
|
|
2022
Q4 | $14.5K | Buy |
525
+501
| +2,088% | +$12.3K | ﹤0.01% | 5402 |
|
|
2022
Q3 | $1K | Sell |
24
-1
| -4% | -$33 | ﹤0.01% | 6352 |
|
|
2022
Q2 | $1K | Sell |
25
-4,362
| -99% | -$197K | ﹤0.01% | 6516 |
|
|
2022
Q1 | $272K | Sell |
4,387
-13,002
| -75% | -$769K | ﹤0.01% | 4805 |
|
|
2021
Q4 | $1.23M | Sell |
17,389
-24,861
| -59% | -$1.77M | ﹤0.01% | 3955 |
|
|
2021
Q3 | $2.95M | Sell |
42,250
-69
| -0.2% | -$5.49K | ﹤0.01% | 3341 |
|
|
2021
Q2 | $3.52M | Buy |
42,319
+17,626
| +71% | +$1.25M | ﹤0.01% | 3184 |
|
|
2021
Q1 | $1.35M | Buy |
24,693
+18,926
| +328% | +$921K | ﹤0.01% | 4029 |
|
|
2020
Q4 | $247K | Sell |
5,767
-4,592
| -44% | -$171K | ﹤0.01% | 4974 |
|
|
2020
Q3 | $312K | Buy |
10,359
+3,740
| +57% | +$126K | ﹤0.01% | 4686 |
|
|
2020
Q2 | $206K | Buy |
6,619
+1,571
| +31% | +$42.3K | ﹤0.01% | 4890 |
|
|
2020
Q1 | $111K | Buy |
5,048
+483
| +11% | +$13.1K | ﹤0.01% | 5007 |
|
|
2019
Q4 | $139K | Sell |
4,565
-524
| -10% | -$15.1K | ﹤0.01% | 5156 |
|
|
2019
Q3 | $157K | Sell |
5,089
-1,573
| -24% | -$39.1K | ﹤0.01% | 5102 |
|
|
2019
Q2 | $134K | Sell |
6,662
-1,767
| -21% | -$51.8K | ﹤0.01% | 5177 |
|
|
2019
Q1 | $363K | Buy |
8,429
+2,814
| +50% | +$102K | ﹤0.01% | 4520 |
|
|
2018
Q4 | $179K | Buy |
5,615
+1,746
| +45% | +$68.8K | ﹤0.01% | 4988 |
|
|
2018
Q3 | $203K | Buy |
3,869
+205
| +6% | +$11.5K | ﹤0.01% | 4997 |
|
|
2018
Q2 | $196K | Buy |
3,664
+77
| +2% | +$3.94K | ﹤0.01% | 5049 |
|
|
2018
Q1 | $180K | Buy |
3,587
+342
| +11% | +$15.3K | ﹤0.01% | 5031 |
|
|
2017
Q4 | $107K | Buy |
3,245
+3,091
| +2,007% | +$104K | ﹤0.01% | 5277 |
|
|
2017
Q3 | $6K | Hold |
154
| – | – | ﹤0.01% | 5981 |
|
|
2017
Q2 | $4K | Sell |
154
-200
| -56% | -$4.95K | ﹤0.01% | 5960 |
|
|
2017
Q1 | $9K | Hold |
354
| – | – | ﹤0.01% | 5902 |
|
|
2016
Q4 | $11K | Buy |
354
+154
| +77% | +$3.92K | ﹤0.01% | 5773 |
|
|
2016
Q3 | $5K | Buy |
+200
| New | +$5.55K | ﹤0.01% | 5909 |
|
|
2016
Q2 | – | Sell |
-1,084
| Closed | -$33K | – | 6192 |
|
|
2016
Q1 | $33K | Buy |
1,084
+90
| +9% | +$2.55K | ﹤0.01% | 5366 |
|
|
2015
Q4 | $35K | Buy |
994
+357
| +56% | +$12.2K | ﹤0.01% | 5411 |
|
|
2015
Q3 | $24K | Sell |
637
-7,648
| -92% | -$356K | ﹤0.01% | 5489 |
|
|
2015
Q2 | $472K | Buy |
8,285
+5,281
| +176% | +$301K | ﹤0.01% | 4129 |
|
|
2015
Q1 | $175K | Sell |
3,004
-402
| -12% | -$21.6K | ﹤0.01% | 4479 |
|
|
2014
Q4 | $193K | Buy |
3,406
+2,806
| +468% | +$134K | ﹤0.01% | 4445 |
|
|
2014
Q3 | $25K | Hold |
600
| – | – | ﹤0.01% | 5201 |
|
|
2014
Q2 | $27K | Hold |
600
| – | – | ﹤0.01% | 5228 |
|
|
2014
Q1 | $28K | Hold |
600
| – | – | ﹤0.01% | 5124 |
|
|
2013
Q4 | $28K | Sell |
600
-550
| -48% | -$24K | ﹤0.01% | 4903 |
|
|
2013
Q3 | $46K | Buy |
1,150
+132
| +13% | +$5.19K | ﹤0.01% | 4695 |
|
|
2013
Q2 | $36K | Buy |
+1,018
| New | +$39K | ﹤0.01% | 4695 |
|
Other funds holding HBIO
AE
HP
MIM
GIM
Wells Fargo's HBIO Position: Q3 2025 in Review
Wells Fargo sold out of Harvard Bioscience (HBIO) in Q3 2025, closing a stake of 80 shares — an estimated $356 sold.
Wells Fargo first reported a position in HBIO in Q2 2013 and held it in 48 quarters. The position peaked at $3.52M in Q2 2021. 59 funds tracked by Wall St. Rank hold HBIO as of Q3 2025.
- Wells Fargo reported no remaining Harvard Bioscience position as of Q3 2025 after selling out during the quarter.
- Wells Fargo sold 80 Harvard Bioscience shares in Q3 2025, an estimated $356.
- Wells Fargo first reported a position in Harvard Bioscience in Q2 2013 and held it in 48 quarters.
- Wells Fargo's Harvard Bioscience position peaked at $3.52M in Q2 2021.
- 59 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2025.
Based on Wells Fargo's 13F filing for Q3 2025, filed 13 Nov 2025.